High Impact(Breakthrough) Medicines for All

Highlightll is a clinical stage biopharmaceutical company focusing on both peripheral and central autoimmune/inflammatory diseases. We strive to discover breakthrough medicines which would have a high impact on health care. We leverage resources and expertise worldwide and combine them with our unique perspectives to solve challenging medical problems. Our lead programs are the world's‌ first highly potent and selective dual TYK2/JAK1 inhibitors. TLL-018, a peripheral TYK2/JAK1 inhibitor, is in Phase 3 trials for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA), while TLL-041, the world first brain-penetrant TYK2/JAK1 inhibitor was licensed to Biohaven in 2023. Biohaven advanced the BHV-8000/TLL-041 program to a global Phase II/III pivotal trial in Parkinson’s disease in May 2025. NLRP3 is our second platform where we are developing HL-400 for neurodegenerative diseases and HL-450 for peripheral diseases.

Read More